Orthocell Ltd (ASX:OCC, OTC:ORHHF) earlier this week reported new real-world data supporting its Remplir nerve repair product, with managing director and CEO Paul Anderson highlighting a 90% success rate across a broad patient cohort as the company positions for revenue growth.
Anderson said the dataset marked an important milestone, demonstrating strong outcomes across patients aged between 14 and 82 undergoing a range of nerve repair procedures. He noted that the breadth of the data added weight to the product’s clinical credibility, stating that it “contributes to a really strong data pool” for Remplir.
The company is focusing on nerve reconstruction and protection, particularly in reducing scar tissue formation, with the latest results reinforcing the product’s consistency and predictability in surgical outcomes. Anderson indicated that this is a key factor driving adoption among surgeons, as improved reliability can simplify clinical decision-making.
Orthocell has already established a solid foundation in Australia, where Remplir has been approved for around three years. The product is now used by more than 300 surgeons across over 250 hospitals, with reimbursement secured in the private healthcare system. This level of penetration has helped validate both the scientific and commercial proposition of the device.
Looking ahead, the company is leveraging this domestic success to accelerate expansion into the United States. Anderson said growing uptake in that market is beginning to translate into increased revenues, with Orthocell nearing what he described as a “material revenue inflection point.” This suggests a potential shift towards stronger top-line growth as awareness and access improve.
From a commercial standpoint, Remplir is positioned as a competitively priced, collagen-based medical device, supported by a global pricing parity strategy. Manufacturing is currently based in Australia, allowing Orthocell to retain margins, protect intellectual property, and maintain control over supply.
Overall, the combination of strong clinical data, increasing surgeon adoption, and expansion into a major healthcare market such as the US represents a series of near-term catalysts for the company, as it seeks to scale revenues and broaden the reach of its nerve repair technology.
Key highlights
- Remplir achieves 90% success rate in real-world patient data
- Data spans broad demographic (ages 14–82) and multiple interventions
- Product supports nerve reconstruction and scar tissue reduction
- Fully reimbursed in Australia’s private healthcare system
- Over 300 surgeons and 250 hospitals using Remplir in Australia
- Expansion into the US market gaining momentum
- Company approaching a material revenue inflection point
- Australian manufacturing supports margins and IP protection
Proactive: Welcome back to Proactive Investors. My name is Kerry Stevenson. I’m joined by Paul Anderson, managing director and CEO of Orthocell (ASX: OCC). The company has a product called Remplir, a nerve regeneration product now supported by real-world data. Paul, welcome back—give us the update.
Paul Anderson: Thanks for having me. This announcement is a really important dataset for us. It shows a 90% success rate across a broad range of patient interventions. We are focused on nerve reconstruction and protection, particularly reducing scar tissue. This data spans patients aged 14 through to 82, making it a robust and meaningful dataset for Remplir.
Proactive: Is the product likely to be prohibitively expensive?
Paul Anderson: No, it is fully reimbursed in the private healthcare system in Australia and is moderately priced. We focus on maintaining mutually beneficial relationships with hospitals and governments. We also apply global pricing parity. Remplir is a collagen-based medical device and is competitively positioned.
Proactive: Let’s talk about the investment case. Why should investors pay attention now?
Paul Anderson: This data is critical for marketing and demonstrates strong utility and high success rates to surgeons globally. It leads to more predictable outcomes and increased uptake. We are seeing growing revenues, particularly from the United States, and are approaching a material revenue inflection point.
Proactive: Is your focus more on Australia or the US?
Paul Anderson: We launched in Australia first and now have over 300 surgeons and 250 hospitals using Remplir. This validates the product and provides a strong foundation for expansion into the US, where our experience is helping guide adoption.
Proactive: Where is the product manufactured?
Paul Anderson: We manufacture in Australia. This allows us to maintain margins, protect intellectual property, and strengthen supply chain control.
Proactive: Great to speak with you again.
Paul Anderson: Thanks, always a pleasure.